Key result
AAV-mediated telomerase overexpression protects against doxorubicin-induced apoptosis and rescues cardiac function in preclinical models.
Why the study?
Clinical use of doxorubicin is restricted by severe cardiotoxicity linked to reactive oxygen species, leading researchers to hypothesize that telomerase overexpression could prevent this toxicity.
Does AAV-mediated telomerase gene therapy prevent doxorubicin-induced cardiotoxicity in preclinical models?
Does AAV-mediated telomerase gene therapy prevent doxorubicin-induced cardiotoxicity in preclinical models?
Telomerase gene therapy protects against doxorubicin-induced cardiotoxicity by preserving mitochondrial function and preventing apoptosis in preclinical models.
No takes yet. Share an insight, caveat, or question.
Should not yet change cardio-oncology practice; leaves open telomerase AAV therapy for doxorubicin cardiotoxicity in humans.
Chatterjee et al. (2020) studied Doxorubicin-induced cardiotoxicity. AAV-mediated telomerase gene therapy was evaluated on Doxorubicin-mediated apoptosis and cardiac function. AAV-mediated overexpression of telomerase protected the heart from doxorubicin-mediated apoptosis and rescued cardiac function in in vitro and in vivo models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: